Meindl et al. [9,25] and Osorio et al. [16] state that RAD51C mutations predispose to breast and ovarian cancer whereas Loveday et al. [17] estimated the relative risk of ovarian cancer for RAD51C protein truncating mutation carriers to be 5.88 but no elevated risk for breast cancer. This evidence concerns the gene RAD51C and ovarian cancer.